Stifel analyst Thomas Stephan lowered the firm’s price target on Sight Sciences (SGHT) to $13 from $15 and keeps a Buy rating on the shares. There are “clear indications” from the likes of UnitedHealth (UNH) and Humana (HUM) that outpatient surgery volumes have accelerated of late, says the firm, which believes cataract surgery “likely falls under this umbrella” and thinks should mean MIGS trends are also solid. However, Sight Sciences shares are likely to “remain in a holding-pattern until the LCD outcomes unfold,” says the analyst, who adds that TearCare appears undervalued and sees a significant catalyst in the SAHARA 6-month readout in the coming months.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGHT:
- Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)
- Sight Sciences announces Cigna expanded coverage of Glaucoma procedures
- Sight Sciences Announces Addition of New Director Catherine Mazzacco
- Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical System Technology
- Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry
